- Home
- PEPG vs AVTX Comparison
PEPG vs AVTX Comparison
Compare PEPG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- AVTX
- Stock Information
- Founded
- PEPG 2018
- AVTX 2011
- Country
- PEPG United States
- AVTX United States
- Employees
- PEPG N/A
- AVTX N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- AVTX Health Care
- Exchange
- PEPG Nasdaq
- AVTX Nasdaq
- Market Cap
- PEPG 52.4M
- AVTX 57.4M
- IPO Year
- PEPG 2022
- AVTX 2015
- Fundamental
- Price
- PEPG $1.38
- AVTX $3.60
- Analyst Decision
- PEPG Buy
- AVTX Strong Buy
- Analyst Count
- PEPG 3
- AVTX 6
- Target Price
- PEPG $9.67
- AVTX $34.20
- AVG Volume (30 Days)
- PEPG 228.0K
- AVTX 53.9K
- Earning Date
- PEPG 05-08-2025
- AVTX 05-12-2025
- Dividend Yield
- PEPG N/A
- AVTX N/A
- EPS Growth
- PEPG N/A
- AVTX N/A
- EPS
- PEPG N/A
- AVTX N/A
- Revenue
- PEPG N/A
- AVTX $441,000.00
- Revenue This Year
- PEPG N/A
- AVTX N/A
- Revenue Next Year
- PEPG N/A
- AVTX N/A
- P/E Ratio
- PEPG N/A
- AVTX N/A
- Revenue Growth
- PEPG N/A
- AVTX N/A
- 52 Week Low
- PEPG $0.88
- AVTX $4.15
- 52 Week High
- PEPG $19.30
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- PEPG 46.11
- AVTX 24.71
- Support Level
- PEPG $1.46
- AVTX $4.80
- Resistance Level
- PEPG $1.66
- AVTX $5.26
- Average True Range (ATR)
- PEPG 0.17
- AVTX 0.43
- MACD
- PEPG 0.01
- AVTX -0.04
- Stochastic Oscillator
- PEPG 43.40
- AVTX 10.10
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).